# ATR-12 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/atr-12

> ATR-12, sponsored by Azitra, Inc. (AZTR): 5 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | ATR-12 |
| Codes | ATR-12 |
| Sponsor | Azitra, Inc. (AZTR) https://sec-api.dev/companies/aztr/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### January 27, 2023: trial start

- Status: completed. Date confidence: exact. Stage: 1.
- First seen 2024-11-12, last confirmed 2026-05-13.
- SEC Form 10-Q (accession 0001701478-26-000028): "On January 27, 2023, we received notification from the FDA that the "study may proceed" with respect to the proposed Phase 1b clinical trial, and in August 2024 we initiated dosing the first patient in the ATR-12 Phase 1b clinical trial." https://www.sec.gov/Archives/edgar/data/1701478/000170147826000028/aztr-20260331.htm
- SEC Form 10-K (accession 0001701478-26-000013): "On January 27, 2023, we received notification from the FDA that the "study may proceed" with respect to the proposed Phase 1b clinical trial, and in August 2024 we initiated dosing the first patient in the ATR-12 Phase 1b clinical trial." https://www.sec.gov/Archives/edgar/data/1701478/000170147826000013/aztr-20251231.htm
- SEC registration statement (S-1) (accession 0001493152-25-027067): "On January 27, 2023, we received notification from the FDA that the "study may proceed" with respect to the proposed Phase 1b clinical trial, and in August 2024 we initiated dosing the first patient in its Phase 1b clinical trial evaluating ATR-12." https://www.sec.gov/Archives/edgar/data/1701478/000149315225027067/forms-1.htm
- SEC Form 10-Q (accession 0001701478-25-000050): "On January 27, 2023, we received notification from the FDA that the "study may proceed" with respect to the proposed Phase 1b clinical trial, and in August 2024 we initiated dosing the first patient in the ATR-12 Phase 1b clinical trial." https://www.sec.gov/Archives/edgar/data/1701478/000170147825000050/aztr-20250930.htm
- SEC Form 10-Q (accession 0001701478-25-000040): "On January 27, 2023, we received notification from the FDA that the "study may proceed" with respect to the proposed Phase 1b clinical trial, and in August 2024 we initiated dosing the first patient in the ATR-12 Phase 1b clinical trial." https://www.sec.gov/Archives/edgar/data/1701478/000170147825000040/aztr-20250630.htm
- SEC Form 10-Q (accession 0001701478-25-000018): "On January 27, 2023, we received notification from the FDA that the "study may proceed" with respect to the proposed Phase 1b clinical trial, and in August 2024 we initiated dosing the first patient in the ATR-12 Phase 1b clinical trial." https://www.sec.gov/Archives/edgar/data/1701478/000170147825000018/aztr-20250331.htm
- SEC Form 10-K (accession 0001701478-25-000012): "On January 27, 2023, we received notification from the FDA that the "study may proceed" with respect to the proposed Phase 1b clinical trial, and in August 2024 we initiated dosing the first patient in its Phase 1b clinical trial evaluating ATR-12." https://www.sec.gov/Archives/edgar/data/1701478/000170147825000012/aztr-20241231.htm
- SEC Form 10-Q (accession 0001701478-24-000012): "On January 27, 2023, we received notification from the FDA that the "study may proceed" with respect to the proposed Phase 1b clinical trial, and in August 2024 we initiated dosing the first patient in its Phase 1b clinical trial evaluating ATR-12." https://www.sec.gov/Archives/edgar/data/1701478/000170147824000012/aztr-20240930.htm

### Dec 2023: trial start

- Status: completed. Date confidence: month. Stage: 1.
- First seen 2024-11-12, last confirmed 2026-11-12.
- SEC Form 10-Q (accession 0001701478-26-000049): "After submitting post-IND manufacturing reports, we have commenced operating activities for our Phase 1b clinical trial in December 2023, and we dosed our first patient in August 2024." https://www.sec.gov/Archives/edgar/data/1701478/000170147826000049/aztr-20260930.htm
- SEC Form 10-Q (accession 0001701478-26-000028): "After submitting post-IND manufacturing reports, we have commenced operating activities for our Phase 1b clinical trial in December 2023, and we dosed our first patient in August 2024." https://www.sec.gov/Archives/edgar/data/1701478/000170147826000028/aztr-20260331.htm
- SEC Form 10-K (accession 0001701478-26-000013): "After submitting post-IND manufacturing reports, we have commenced operating activities for our Phase 1b clinical trial in December 2023, and dosed our first patient in August 2024." https://www.sec.gov/Archives/edgar/data/1701478/000170147826000013/aztr-20251231.htm
- SEC Form 10-K (accession 0001701478-26-000013): "After submitting post-IND manufacturing reports, we have commenced operating activities for our Phase 1b clinical trial in December 2023, and we dosed our first patient in August 2024." https://www.sec.gov/Archives/edgar/data/1701478/000170147826000013/aztr-20251231.htm
- SEC registration statement (S-1) (accession 0001493152-25-027067): "After submitting post-IND manufacturing reports, we have commenced operating activities for our Phase 1b clinical trial in December 2023, and we dosed our first patient in August 2024." https://www.sec.gov/Archives/edgar/data/1701478/000149315225027067/forms-1.htm
- SEC Form 10-Q (accession 0001701478-25-000050): "After submitting post-IND manufacturing reports, we have commenced operating activities for our Phase 1b clinical trial in December 2023, and we dosed our first patient in August 2024." https://www.sec.gov/Archives/edgar/data/1701478/000170147825000050/aztr-20250930.htm
- SEC Form 10-Q (accession 0001701478-25-000040): "After submitting post-IND manufacturing reports, we have commenced operating activities for our Phase 1b clinical trial in December 2023, and we dosed our first patient in August 2024." https://www.sec.gov/Archives/edgar/data/1701478/000170147825000040/aztr-20250630.htm
- SEC Form 10-Q (accession 0001701478-25-000018): "After submitting post-IND manufacturing reports, we have commenced operating activities for our Phase 1b clinical trial in December 2023, and we dosed our first patient in August 2024." https://www.sec.gov/Archives/edgar/data/1701478/000170147825000018/aztr-20250331.htm
- SEC Form 10-K (accession 0001701478-25-000012): "After submitting post-IND manufacturing reports, we have commenced operating activities for our Phase 1b clinical trial in December 2023, and we have dosed our first patient in August 2024." https://www.sec.gov/Archives/edgar/data/1701478/000170147825000012/aztr-20241231.htm
- SEC Form 10-Q (accession 0001701478-24-000012): "After submitting post-IND manufacturing reports, we have commenced operating activities for our Phase 1b clinical trial in December 2023, and we dosed our first patient in August 2024." https://www.sec.gov/Archives/edgar/data/1701478/000170147824000012/aztr-20240930.htm

### Aug 2024: trial start

- Status: completed. Date confidence: month. Stage: 1.
- First seen 2025-02-24, last confirmed 2025-02-24.
- Press release filed with the SEC (EX-99) (accession 0001493152-25-007980): "In August 2024, we initiated a Phase 1b clinical trial investigating ATR-12 in adult Netherton syndrome patients to assess multiple safety, tolerability, and efficacy endpoints." https://www.sec.gov/Archives/edgar/data/1701478/000149315225007980/ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001493152-25-007980): "August 2024, initiated a Phase 1b clinical trial investigating ATR-12 in adult Netherton syndrome patients." https://www.sec.gov/Archives/edgar/data/1701478/000149315225007980/ex99-1.htm

### late 2025: topline data readout

- Status: scheduled. Date confidence: half. Stage: 1.
- First seen 2025-02-24, last confirmed 2025-05-13.
- Press release filed with the SEC (EX-99) (accession 0001641172-25-009996): "ATR-12, our lead program targeting the rare, chronic and devastating Netherton syndrome, we expect to provide initial safety data from our Phase 1b trial in the first half of 2025 with topline results expected by year-end 2025." https://www.sec.gov/Archives/edgar/data/1701478/000164117225009996/ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001493152-25-007980): "Initial safety data from this trial is expected in the first half of 2025 with topline results by year-end 2025."" https://www.sec.gov/Archives/edgar/data/1701478/000149315225007980/ex99-1.htm

### Q1 2026: topline data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2025-12-10, last confirmed 2025-12-10.
- SEC registration statement (S-1) (accession 0001493152-25-027067): "We reported initial clinical safety results in the first half of 2025, and expect to report topline data in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1701478/000149315225027067/forms-1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/atr-12.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ATR-12 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/atr-12

```bibtex
@misc{secapidev_pdufa_atr_12_20261116,
  title        = {ATR-12 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/atr-12}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_atr_12_20261116","title":"ATR-12 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/atr-12","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
